Bispecific antibodies (bsAbs) combine the capabilities of two antibodies to recognize several antigens or epitopes simultaneously. Such a “two-target” feature means that interest in their utilization for therapeutic applications has developed significantly.
As the bsAb technology stage has advanced and developed, target combination selection has become critical to competitiveness. Currently, the most frequent target combinations among bsAb programs in development are CD3 and tumor surface targets. The novel immune cell targets might potentially provide more alternatives for target combinations in the future.
Hot Targets
Image Credit: ACROBiosystems
There are free samples available for bsAb hot targets.
CD3 Proteins
Features
- Provides excellent bioactivity and batch-to-batch uniformity
- Bioactivity was validated using clinical bispecific antibodies
- MALS verified heterodimer
- Include various tags and species
Image Credit: ACROBiosystems
Table 1. Source: ACROBiosystems
| Molecule |
Cat. No. |
Species |
Product Description |
Structure |
| CD3E & CD3D |
CDD-H5255 |
HEK293 |
Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc Tag&Fc Tag (MALS verified)New |
|
| CDD-H52Wa |
HEK293 |
Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified)Hot |
|
| CDD-H82W6 |
HEK293 |
Biotinylated Human CD3 epsilon&CD3 delta Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)Hot |
|
| CDD-H52W1 |
HEK293 |
Human CD3 epsilon & CD3 delta Heterodimer Protein, His Tag&Tag Free (MALS verified)Hot |
|
| CDD-H5258 |
HEK293 |
Human CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin |
|
| CDD-H82F6 |
HEK293 |
Biotinylated Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His,Avitag™&Fc,Flag,Avitag™ (MALS verified) |
|
| CDD-H82W0 |
HEK293 |
Biotinylated Human CD3E&CD3D Heterodimer Protein, Fc, His Tag&Fc, Flag Tag, ultra sensitivity (primary amine labeling) (MALS verified) |
|
| CDD-C5259 |
HEK293 |
Cynomolgus CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin |
|
| CDD-C52W4 |
HEK293 |
Cynomolgus CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| CDD-C52W9 |
HEK293 |
Cynomolgus CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified) |
|
| CDD-C82W6 |
HEK293 |
Biotinylated Cynomolgus CD3E&CD3D Heterodimer Protein, His, Avitag™&Tag Free (MALS verified) |
|
| CDD-M5219 |
HEK293 |
Mouse CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| CDD-M52W2 |
HEK293 |
Mouse CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified) |
|
| CDD-M82W5 |
HEK293 |
Biotinylated Mouse CD3 epsilon&CD3 delta Heterodimer Protein, His, Avitag™&Tag Free |
|
| CDD-R5257 |
HEK293 |
Rat CD3 epsilon&CD3 delta Heterodimer Protein, Llama Fc Tag&Llama Fc Tag (MALS verified) |
|
| CDD-R52D8 |
HEK293 |
Rat CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| CDD-R5259 |
HEK293 |
Rabbit CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin (MALS verified) |
|
| CDD-R52D7 |
HEK293 |
Rabbit CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified) |
|
| MBS-K003 |
|
Human CD3E & CD3D Heterodimer-coupled Magnetic Beads |
|
PD-1/PD-L1 Proteins
Features
- High bioactivity is verified
- Excellent purity and uniformity
- Diverse tags and species
Image Credit: ACROBiosystems
CD47 Proteins
Features
- High bioactivity is verified
- Outstanding purity and uniformity
- Perfect for immunization and inhibitor
Image Credit: ACROBiosystems
Full-length CD20 Proteins
Features
- High bioactivity is verified
- Genuine conformation
- Distinctive nanodisk technology
Image Credit: ACROBiosystems
Bioactivity Analysis of Bispecific Antibody
It is critical to characterize and evaluate pharmacokinetic (PK)/PD. Quality factors such as antigen specificity, affinity, on—and off-rates, avidity (for bispecific antibodies that target two molecules on the same cell), potency, process-related impurities such as aggregates, fragments, and homodimers, stability, and half-life could impact pharmacology and should be investigated.
However, bispecific antibodies can exist in both biologically active and inert forms. As a result, it is critical to identify the bispecific antibody form(s) that are pharmacologically relevant to the PK/PD test and conduct validated tests to assess the appropriate form(s).
BsAb’s synergetic action reduces the dosage, necessitating a more sensitive assay for analysis.
Case Study 1: Antigen-Antibody Affinity
Figure 1. Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3 X BCMA) and then add Biotinylated BCMA Fc, Avitag (Cat. No. BC7-H82F0) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4 ng/mL. Image Credit: ACROBiosystems
Case Study 2: FcR-Antibody Affinity
Figure 2. Binding assay between bsAb and Fc receptor. Image Credit: ACROBiosystems
Case Study 3: Intact Assay of bsAb
Figure 3. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, Fc, Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4 ng/mL (Intact assay). Image Credit: ACROBiosystems
Methodology Validation
Table 2. Source: ACROBiosystems
